BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Regulation FD Disclosure

BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01.

Regulation FD Disclosure.

On June 1, 2017, BioPharmX Corporation (the Company) issued a
press release announcing comprehensive results from the Companys
phase 2b clinical trial evaluating its product candidate BPX-01,
a hydrophilic topical minocycline gel product candidate for the
treatment of moderate-to-severe acne. A copy of the press release
is furnished as Exhibit 99.1 to this report and is incorporated
herein by reference. The Company also presented these results at
a State of Acne symposium in New York City on June 1, 2017. The
event was webcast live and the event and presentation materials
will be archived for 90 days at

Media

The information in this Current Report on Form 8-K under Item
7.01, including the information contained in Exhibit 99.1, is
being furnished to the Securities and Exchange Commission, and
shall not be deemed to be filed for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
and shall not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by a
specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)

Exhibit No. Description
99.1 Press Release, dated June 1, 2017 by BioPharmX Corporation


About BIOPHARMX CORPORATION (NYSEMKT:BPMX)

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.

BIOPHARMX CORPORATION (NYSEMKT:BPMX) Recent Trading Information

BIOPHARMX CORPORATION (NYSEMKT:BPMX) closed its last trading session down -0.047 at 0.587 with 2,510,423 shares trading hands.

An ad to help with our costs